Immunotherapy Stocks Power Higher on Celgene-Juno Deal – TheStreet.com
TheStreet.com |
Immunotherapy Stocks Power Higher on Celgene-Juno Deal
TheStreet.com Immunotherapy Stocks Power Higher on Celgene-Juno Deal. Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics’ announced sale to Celgene. ByArmie Margaret Lee. Jan 22 … |
Business Insider |
The hottest thing in cancer drug development just won a $9 billion endorsement
Business Insider Juno is known for its experimental, highly personalized cancer treatments called CAR T-cell therapy, which harnesses the body’s immune system to go after certain blood cancers. It’s part of a new field of cancer therapies that . In 2017, the FDA … Celgene to buy Juno for $9 billion to boost CAR–T expertiseReuters UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodesEndpoints News Celgene to buy Juno Therapeutics for about $9 billion – CNBC.comCNBC STAT –Business Wire (press release) –Zacks Investment Research –SEC.gov all 163 news articles » |
FierceBiotech |
Eureka nets $60M to take T–cell therapy into the clinic
FierceBiotech The FDA approved the first two CAR-T treatments for blood cancers—Novartis’ Kymriah and Kite and Gilead’s Yescarta—in 2017, but the agency still flags cytokine release syndrome and neurotoxicity as “significant safety issues” tied to this type of … Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor …Business Wire (press release) |